Standout Papers
Citation Impact
Citing Papers
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
2013
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel
2003
Cancer statistics, 2020
2020 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
2008 Standout
Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib
2017
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
2003
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
1993 Standout
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
2004 Standout
Cancer Metastasis: Building a Framework
2006 Standout
Lung Cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Renal Tumors in the Birt-Hogg-Dubé Syndrome
2002
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
2004
Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum
2007
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study
2003
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model
2003
Lung Cancer and Lung Stem Cells
2006
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Hereditary Colorectal Cancer
2003 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Adjuvant therapy in pancreatic cancer: historical and current perspectives
2003
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro
2007
Current strategies in the management of hormone refractory prostate cancer
2003
Mechanisms of Bone Metastasis
2004 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Wnt signalling in stem cells and cancer
2005 StandoutNature
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice
2007 StandoutNobel
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Couples' Experiences With Prostate Cancer: Focus Group Research
2002
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
2003
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
2006 StandoutNature
Health Related Quality of Life Patterns in Patients Treated With Interstitial Prostate Brachytherapy for Localized Prostate Cancer—Data From CaPSURE
2003
A molecular role for lysyl oxidase in breast cancer invasion.
2002
A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer
2004
Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
2003
Immunogenicity of therapeutic recombinant immunotoxins
2016
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
2003
Self-Renewal and Cancer of the Gut: Two Sides of a Coin
2005 Science
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
2006
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
Promoter Hypermethylation of Multiple Genes in Sputum Precedes Lung Cancer Incidence in a High-Risk Cohort
2006
Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome
2004
The Expanding Role of Systemic Therapy in Head and Neck Cancer
2004
Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
2003
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2004
Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial
2004
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
2006
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Missense mutations of the BRAF gene in human lung adenocarcinoma.
2002
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial
2003
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
SIGNALING PATHWAYS IN INTESTINAL DEVELOPMENT AND CANCER
2004
Breast Cancer in Men
2002 Standout
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Works of Anish Thomas being referenced
Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States
2015
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
2014
Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
2016
Cancer Statistics, 2002
2002 Standout
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
2013